2015 st. jude annual report

Finding cures. Saving children.® 2015 St. Jude Annual Report|

St. Jude Patient

Trippacute myeloid leukemia

2Meet Sebastian

Our Mission

4

A Great Hospital 6

A Great Research Institution 12

A Great Charity 22

Leadership & Service 30

Financials 40

St. Jude Children’s Research Hospital® is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

Our purpose is clear: Finding cures. Saving children.

®

Finding cures. Saving children.® 2015 St. Jude Annual Report | Page 2

Meet Sebastian age 8 medulloblastoma

Sebastian was always a happy, active boy. Nothing prepared his family for the day in June 2014 when they learned he suffered from a rare brain cancer called medulloblastoma.

“We were devastated,” said his mother, Belen.

Sebastian’s doctor sent his family to St. Jude Children’s Research Hospital for his care. Sebastian’s treatment at St. Jude included chemotherapy and radiation therapy. He recently finished t eatment and now visits St. Jude every three months for scans.

“Ther e are no words to describe St. Jude,” Belen said. “Everything is designed so the fami ly only worries about loving their child. We’re grateful there is a place like St. Jude.”

|

St. Jude Patient

Bentonacute lymphoblastic leukemia


Our Mission The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder, Danny Thomas, no child is denied treatment based on race, religion or a family’s ability to pay.

ALSAC is the fundraising and awareness organization for St. Jude. ALSAC’s sole mission is to raise the funds and awareness necessary to operate and maintain St. Jude.

For more information, please visit stjude.org.

St. Jude Patient

Brycesickle cell disease


A Great Children’s HospitalEveryone at St. Jude is committed to providing the absolute best in patient care to the children who walk through our doors.

We put every child and their family at the center of our efforts to fight the diseases that th eaten young lives. Even before a family arrives at the hospital, a dedicated team is preparing to not only treat their child, but also to support them during one of the toughest times that families ever face.As innovators in patient care, we are by their side at every step, through every decision, providing a seamless network of support for our patients and their families. And the cost of this exceptional care is never a burden: No family ever receives a bill from St. Jude for treatment, travel, housing or food – because we believe all a family should worry about is helping their child live.

St. Jude Patient

Addisionglioma

St. Jude Patient

JuliaWilms tumor

We want the kids of St. Jude to thrive – even while undergoing treatment. They are not just a patient. They are children and teens with hopes and dreams and wishes, and so we celebrate their lives and milestones every day. We cheer them on as they master new school work, walk the red carpet at the St. Jude Teen Formal and dress up to go trick-or-treating throughout the hospital at Halloween.

We don’t stop there. We follow our patients’ progress after treatment ends, through the largest long-term follow-up clinic for childhood cancer patients in the country. We care about how their treatment affects their lives as adults, and so we are leading one of the country’s most ambitious studies of childhood cancer survivors.

We are committed to providing the very best patient care – because we want the very best for the kids of St. Jude.

St. Jude treats patients from

all50 states& around the world

Treatments invented at St. Jude have helped push the %

overall childhood survival rate from

201962

80%tomorethan

today

Meet Liam age 3 | ATRT

Three-year-old Liam is in some ways a typical little man, says his mom. “He likes to watch TV and eat popcorn.” But in other ways, Liam is anything but typical. In 2014, a very large mass was found in the left frontal lobe of his brain. It proved to be ATRT, a rare and aggressive form of cancer.

Two days after the tumor was discovered, Liam underwent his first brain surgery in his home state of Ohio. Devastated and numb, Liam’s family didn’t know what to do next, until his mom spoke with the father of another little child with ATRT who had been finished with t eatment a year and was still cancer-free. That child had been treated at St. Jude Children’s Research Hospital. “After I got off the phone with him, for the first time, I felt hopeful,” said Liam s mom.

At St. Jude, Liam’s treatment included additional surgery, chemotherapy and proton beam therapy. Liam is now finished with t eatment and returns to St. Jude regularly for checkups.

“ Because we haven’t had to worry about housing or medical costs,” said his mom, “we’ve been able to all be together as a family. It opens your eyes to how even though bad things can happen, there’s still things to be grateful for.”


A Great Research InstitutionWhen St. Jude opened in 1962, cancer was a virtual death sentence for children – only 20% survived.

In the case of acute lymphoblastic leukemia, the most common form of childhood cancer, the survival rate was a grim 4%. St. Jude tackled those somber statistics head on and forever changed the fates of children diagnosed with cancer.

Today, treatments invented at St. Jude have helped push the overall survival rate to more than 80% and, at St. Jude, the survival rate for acute lymphoblastic leukemia is now 94%, the highest in the nation.

We won’t stop until no child dies from cancer.We are working at the leading edge of science to discover better ways to diagnose and treat childhood cancer and other life-threatening diseases such as sickle cell disease. At St. Jude, we seek both cures and ways to prevent these diseases.

And we freely share our discoveries so that doctors and scientists around the world can use this knowledge to save thousands more children.

es. Saving children.® 2015 St. Jude Annual Report | Page 14Finding cur

FY15 ResearchHighlights

Genomic analysis reveals that high-risk leukemia subtype becomes more common with age

A study led by St. Jude offers vital information about a high-risk subtype of the most common childhood cancer – acute lymphoblastic leukemia (ALL). Patients with the subtype - called Ph-like ALL - are less likely to survive. The report shows that becomes more common with age, but may respond well to drugs used to treat leukemia in adults.

September 2014 | New England Journal of Medicine

Gene sequencing projects link two mutations to Ewing sarcoma subtype with poor prognosis

An international collaboration has identified a subtype of Ewing sarcoma linked to low survival rates. The study was conducted by the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project and the Institut Curie-Inserm of France. The finding lays the groundwork for more effective diagnosis and treatment of the bone and soft tissue tumor.

November 2014 | Cancer Discovery

Our laboratories may not be in every community, but our discoveries are.

Good news for young patients with a leukemia subtype associated with a poor prognosis

A study from St. Jude offers hope for children with a subtype of leukemia known for poor survival rates. The study shows that adjusting treatment based on early response to chemotherapy can make a lifesaving difference to young patients with this type of disease.

September 2014 Journal of Clinical Oncology |

Avian influenza virus isolated in harbor seals poses a threat to humans

Avian influenza is a worldwide health concern. Avian influenza strains such as H5N1 and H7N9 a e known to be extremely dangerous to human beings. A study led by St. Jude has found that a strain of the avian influenza A H3N8 virus, which killed more than 160 harbor seals in New England in 2011, also poses a threat to people. The findings reinforce the need for continued surveillance of flu viruses circulating among wild and domestic animals.

September 2014 Nature Communications |

Sun damage causes genetic changes that predispose children and adolescents to melanoma.

A study from the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project shows that conventional melanoma is essentially the same disease in children and adults. The findings could lead to better diagnosis an treatment of the disease.

March 2015 Journal of Investigative Dermatology |

Tracking defects caused by brain tumor mutationyields insight to advance targeted therapy

Scientists at St. Jude Children’s Research Hospital have made new progress in a long-term battle to beat the most common pediatric brain tumor, medulloblastoma. Building on previous St. Jude research discoveries, St. Jude scientists found that mutations of a certain gene linked to a subtype of medulloblastoma do not all lead to a single common cell defect. This means treatments targeting these mutations must be tailored for the specific defects.

May 2015 Journal of Molecular Biology

|


Inherited gene variations tied to treatment- related hearing loss in cancer patients

Scientists from St. Jude have found that hearing loss in some young cancer patients treated with cisplatin, a mainstay of cancer treatment, is associated with inherited genetic variations in those patients.

February 2015 | Nature Genetics

Chromosomal rearrangement is the key to progress against aggressive infant leukemia

A study from the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project offers insight into a very aggressive form of acute lymphoblastic leukemia (ALL) that strikes infants. The findings suggest that in most cases of the disease targeting a specific chromosome rearrangement may likely be the key to improved survival.

March 2015 | Nature Genetics

For more information about the groundbreaking medical and scientific work of St.Jude, please see the St. Jude Scientific Report a stjude.org/stjudepublications.

During the past five decades, St. Jude has made remarkable progress toward curing childhood cancer and other life-threatening diseases. But our work is not done.

St. Jude is striving to push cure rates ever higher, while developing tailored treatments to decrease side effects.

To do that, St. Jude plans to double the number of children enrolled in St. Jude-led clinical trials and will create a national referral clinic for rare pediatric cancers. In 2015, the hospital began treating patients in the only proton therapy center dedicated solely to children. St. Jude also began to perform an unparalleled level of DNA sequencing of patients’ tumor and normal cells through the Genomes for Kids clinical study.

St. Jude creates more clinical trials

for cancer than any other children’s hospital

MORE THAN THE NEXT TOP 9 INSTITUTIONS COMBINED

ST. JUDE IS LEADING EFFORTS

OF THE CHILDHOOD CANCER

SURVIVORS STUDY, ONE OF

THE WORLD’S LARGEST STUDIES

OF LONG-TERM CANCER EFFECTS

&


St. Jude Patient

Damienmedulloblastoma

Every year,

about 175,000 the majority of children will not have access to adequate

cases of cancer will be diagnosed in diagnosis & treatmentchildren around the world.

&


Our St. Jude global effort was created to help improve survival rates for children with cancer and other life-threatening diseases around the globe. Through the development of partner sites and regional networks, and our cure4kids.org website, we are working with health care professionals across the globe to help erase treatment disparities and improve care for children.

Learn more about the St. Jude international effort at stjude.org/international.

St. Jude Patient

Leaacute myeloid leukemia

Finding cures. Saving children.® 2015 St. Jude Annual Report |

A Great CharityUnlike any other hospital, the majority of funding for St. Jude comes from generous donors.

Thanks to millions of people like you, families never receive a bill from St. Jude for treatment, travel, housing or food – because all a family should worry about is helping their child live.

YOUR DEDICATION TO OUR MISSION comes alive in the

31,000 activities

HELD THROUGHOUT THE COUNTRY EACH YEAR TO RAISE FUNDS & AWARENESS FOR ST. JUDE


IT WILL COST NEARLY

$ 1 billionTO OPERATE ST. JUDE

in 201675%more than of those fund

must be raiseby public contributions

s d


averageMORE

9 mTHAN

illion INDIVIDUAL DONATION

active donors $35THIS IS MADE POSSIBLE BY THE GENEROSITY OF

Meet Phoenixage 5 | retinoblastoma

“ Where would we be today if it weren’t for St. Jude? Lost,” says Pamela, with a sob in her voice.

Pamela’s grandson, 5-year-old Phoenix, became a St. Jude patient on Christmas Day 2012. At the time, he was only 17 months old. “We had noticed that he didn’t have full control of both his eyes. They weren’t always lined up,” Pamela recalls. “And we knew by age 1, he should have that control.”

Phoenix’s doctor back home referred him to St. Jude Children’s Research Hospital, where the terrifying diagnosis was confirmed: bilateral retinoblastoma – cancerous tumors in both eyes. At St. Jude, Phoenix underwent eleven months of chemotherapy.

Today, the cancer is in remission, and Phoenix returns to St. Jude regularly for checkups to make sure it stays that way. Like all St. Jude patients, Phoenix receives this care at no charge to his family. Families never receive a bill from St. Jude for treatment, travel, housing or food – because all a family should worry about is helping their child live.

Phoenix is a budding drummer who loves to sing and dance. “Physically he’s doing good. Emotionally he’s doing good,” says Pamela. “I know St. Jude is the reason he has both his eyes. I tell everyone everywhere I go, St. Jude is amazing. I know God has to be in the midst of it. I don’t think I would have my grandson if we had not gotten to St. Jude.”


Leadership & Service“ Those who work for the good are as those who do the good.”

—Arab proverb in Danny Thomas/ALSAC Pavilion

ALSAC/St. Jude Boards of Directors & Governors

Legacy of Service

The members of the ALSAC/St. Jude Boards of Directors and Governors are volunteers from throughout the United States who serve without compensation. Many represent the second and third generations of their families who have supported St. Jude through service on the Board. An honorary body of emeritus members recognizes distinguished service on the Board by those unable to continue to actively participate.

FY15 ALSAC Board of Directors Officers

Richard M. Unes Construction Chair

Paul J. AyoubAttorneyFirst Vice Chair

James B. Barkate Real Estate/Title Research Second Vice Chair

Frederick R. Harris Manufacturing Secretary

FY15 St. Jude Board of GovernorsOfficers

Terry L. BurmanBusinessChair

Martha Perine Beard Banking First Vice Chair

Camille F. Sarrouf Jr. Attorney Second Vice Chair

Fred P. Gattas Jr. Business Consultant Secretary

FY15 Members

Joyce A. Aboussie Public Relations

Salem A. Abraham Investments

Susan Mack Aguillard, MD Pediatrician

Mahir R. Awdeh, MD Cardiologist

Joseph S. Ayoub Jr. Consultant

Frederick M. Azar, MD Chief of Staff, Orthopedic Surgeon

José BarraMerchandising

Sheryl A. BouriskPublic Relations/Marketing

Robert A. Breit, MD Radiologist

Ann M. Danner Real Estate Developer

Fred P. Gattas III, PharmD Nuclear Pharmacist and Corporate Pharmacy Quality Manager

Ruth Gaviria Marketing

Christopher B. George, MD Physician – Oncology/Hematology

Judy A. Habib Marketing

Gabriel G. Haddad, MD Pediatrics Cancer Genes and Genome Program

Paul K. Hajar Publishing

Charles C. Hajjar Real Estate

Fouad M. Hajjar, MD Pediatric Hematology Oncology

Bruce B. Hopkins Banking

Michael D. McCoy Sheriff

Robert T. Molinet Securities and Corporate Law

Dwayne M. Murray Attorney

James O. Naifeh Jr. Business

Ramzi Nuwayhid Financial Advisor

Thomas J. Penn III NBA Administration

Camille F. Sarrouf Sr. Attorney

Joseph C. Shaker Advertising

Joseph G. Shaker Advertising

George A. Simon II Manufacturing

Michael C. Simon Investments

Paul J. Simon Manufacturing

Terre Thomas Writer

Tony Thomas Producer

Paul H. Wein Attorney

Thomas C. Wertz Finance

Tama Zaydon Investments

Emeritus Members (Non-voting members of the Board)

Thomas G. Abraham Media Production

Jack A. Belz Real Estate

Stephen J. Camer, MD Surgeon

V. Reo Campian Manufacturing

Joseph G. Cory, PhD Professor of Biochemistry

Leslie Dale Communications

Lewis R. Donelson III Attorney

Edward M. Eissey, PhD Educator

George Elias Jr. Attorney

Hasan M. Elkhatib Pharmaceuticals

Sam F. Hamra Attorney

Theodore Hazer Broker

Joseph G. Hyder Broadcasting


Joseph D. Karam Wendy’s Franchise Owner

Richard J. Karam Attorney

James A. Kinney Banking

Julia R. Lester Business

Salli E. LeVanMarketing

Donald G. Mack, MD Pediatrician

George M. Maloof Attorney

Paul J. Marcus Investments

James O. Naifeh Government

David B. Nimer Export-Import

Talat M. Othman Investments

Manal B. Saab Business

Frederick W. Smith Aviation Transportation

Ronald A. Terry Investments

Pat Kerr Tigrett Designer

Robert P. Younes, MD Physician

Ramzi T. Younis, MDPhysician

Ex-Officio Voting Members

Richard C. Shadyac Jr. President and CEO ALSAC/St. Jude

James R. Downing, MD President and CEOSt. Jude Children’s Research Hospital

Chief Governance Officer/ Corporate Secretary

Leah Domitrovic

Epsilon Sigma Alpha

Vicky Farris(Non-elected member)

Scientific Advisory BoardThe Scientific Advisory Board is an autonomous panel of renowned physicians and scientists who help foster the medical and scientific development of St.Jude, providing guidance and insight on research directions, clinical activities and institutional policy.

FY15 ChairMichael P. Link, MD The Lydia J. Lee Professor of PediatricsDivision of Hematology/Oncology Stanford University School of Medicine Lucille Packard Children’s Hospital Stanford

FY15 Vice ChairTheodore S. Lawrence, MD, PhD, FASTRO, FASCO Max S. Wicha, MD Distinguished Professor of OncologyDirector, University of Michigan Comprehensive Cancer CenterChair, Department of Radiation OncologyUniversity of Michigan Medical School

FY15 MembersAndrea Califano, PhD Clyde and Helen Wu Professor of Chemical and Systems Biology Chair, Department of Systems BiologyDirector, JP Sulzberger Columbia Genome CenterAssociate Director, Herbert Irving Comprehensive Cancer Center Columbia University

David S. Eisenberg, DPhil Howard Hughes Medical Institute InvestigatorPaul D. Boyer Professor of Biochemistry and Molecular BiologyUniversity of California at Los Angeles

Patricia A Ganz, MD Distinguished Professor of Health Policy and Management,UCLA Fielding School of Public HealthProfessor of Medicine, UCLA David Geffen School of MedicineDirector, Center for Cancer Prevention & Control Research, Jonsson Comprehensive Cancer CenterUniversity of California at Los Angeles

Todd Golub, MD – Chair Emeritus Howard Hughes Medical Institute InvestigatorChief Scientific Officer and Director, Cancer Program, Broad InstituteProfessor of Pediatrics, Harvard Medical School

David P. Harrington, PhD Professor of Biostatistics, Harvard T.H. Chan School of Public HealthProfessor, Biostatistics and Computational Biology, Dana-Farber Cancer Institute

Mignon L. Loh, MDProfessor of Clinical Pediatrics, Deborah and Arthur Ablin Endowed Chair in Pediatric Molecular OncologyDivision Chief, Hematology/Oncology University of California Benioff Children’s Hospital

Ellis J. Neufeld, MD, PhDAssociate Chief, Division of Hematology/OncologyDana-Farber/Boston Children’s Center for Cancer and Blood DisordersEgan Family Foundation Chair in Transitional Medicine, Harvard Medical School


Jennifer A. Pietenpol, PhDProfessor of Biochemistry, Cancer Biology and OtolaryngologyDirector, Vanderbilt-Ingram Cancer CenterBenjamin F. Byrd Jr. Endowed Chair in OncologyVanderbilt University School of Medicine

Raphael E. Pollock, MD, PhD, FACSProfessor and Director, Division of Surgical OncologyVice Chairman for Clinical Affairs, Department of SurgerySurgeon in Chief, James Comprehensive Cancer CenterSurgeon in Chief, The Ohio State University Health System

David H. Rowitch, MD, PhDProfessor of Pediatrics and Neurological Surgery and Chief of NeonatologyHoward Hughes Medical Institute InvestigatorUniversity of California at San Francisco

Michel Sadelain, MD, PhDDirector, Center for Cell EngineeringStephen and Barbara Friedman ChairMemorial Sloan Kettering Cancer Center

Fundraising & Awareness GuidanceThe volunteers who serve on the Professional Advisory Board and the ALSAC Leadership Board are leaders and experts in their fields who meet regularly to provide guidance to ALSAC on strategic fundraising issues and ways to raise awareness for the St. Jude mission.

FY15 Professional Advisory Board

Marty Belz Peabody Hotel Group

Scott Bowman Global Net Lease

Douglas H. Brooks Brinker International (retired)

Jeb Bush, Jr. Jeb Bush and Associates LLC

Kay Dempsey The Dempsey Companies

Joe DeVivo AngioDynamics Inc.

Michael Francis Farview Associates, LLC

Daisy Fuentes Model and TV Show Host

Don Germano Follett Corporation

Greg Gumbel Sportscaster

Richard Ieyoub Ieyoub Law Firm

George Joulwan U.S. Army General (retired)

J. David KaramSbarro Inc.

Erik Logan OWN, The Oprah Winfrey Network

Michael J. Lynch Bank of America Merrill Lynch

Maguy Maccario Doyle Ambassador of Monaco to the United States and Canada

T. Allan McArtor Airbus Group Inc.

Warren Moon Sports 1 Marketing

Marianne Silver Coyote Logistics LLC

Joe Theismann JRT Associates Inc.

Gary Tobey Haworth Marketing and Media

Eric Trump The Eric Trump Foundation

LuAnn Via Christopher & Banks Corporation

Russell Weiner Domino’s Pizza

Duncan Williams Duncan-Williams Inc.

Craig Witsoe Elo Touch Solutions

FY15 ALSAC Leadership Board

Richard A. Abdoo Wisconsin Energy Corporation (retired)

Marilyn Aboussie Chief Justice of the 3rd Court of Appeals, Texas (retired)

Amin J. Barakat, MD Clinical Professor of PediatricsGeorgetown University Medical Center


Joseph G. (Joe) Bisceglia Jenner & Block LLP

Romero Britto Artist, Britto Central

Nicholas Buttafuoco Buttafuoco, Arce & Price

Pamela Silva Conde Univision Network

Nick Caporella National Beverage Corp.

Terri Carr Wisteria Fashions

Jacqueline Corso Barnes & Noble

Robert ‘Bob’ Corliss Robert Talbott, Inc.CorlissMoore

Chaz Corzine The MWS Group

Trish Coury Gustafson Coldwell Banker Previews International

Joseph K. DeLapp II Visioneering Technologies Inc.

John M. Engquist H & E Equipment Services LLC

Charles A. Feghali NGE Systems LLC

Georgia Hobaica Frasch Philanthropist

Andrew Graves JPMorgan Chase Bank, NA

Marilena Greig Philanthropist & Volunteer

Robert Hureau Pharmaceutical Product Development Inc.

Eileen Hutton Brilliance Audio (retired)

Randa Fahmy Hudome Fahmy Hudome International LLC

Lawrence K. Jensen Commercial Advisors LLC

Linda Johansen-James American Kiosk Management LLC

Albert F. Johary, MD Internal Medicine

Margo R. Keyes Key Development LLC

Wes Kraker Pathmark Transportation

Martha Byrne McMahon Actress

Eunice Mazloom Philanthropist and Volunteer

Lattimore M. Michael Back Yard Burgers Inc. (retired)

William ‘Bill’ N. Morris Jr. The Morris Group

Jerry D. Neal RF Micro Devices (retired)

Scott Nietschmann Boloco Restaurants

William C. Perez Adams and Reese LLP

Nick J. Rahall U.S. House of Representatives

Thomas M. Rashid, MD Urology

Gary J. RotellaAttorney

Andrew San Marco Tradition

Jack Soden Elvis Presley Enterprises Inc.

Gary B. Stone Strategic Thinking One on One

John L. Strauss The John and Bonnie Strauss Foundation

Arnie J. Schwartzman Arent Fox LLP

John Tanner Prime Policy Group

Peter J. Tanous Lepercq Lynx Investment Advisory

Amber Valletta Model and Actress

Mac Winker Former owner and CEO of The Racquet Club of Memphis

St. Jude Executive CommitteeJames R. Downing, MDPresident and Chief Executive Officer

Mary Anna QuinnChief Administrative OfficerExecutive Vice President

Charles Roberts, MD, PhDCancer Center DirectorExecutive Vice President

Carlos Rodriquez-Galindo, MDInternational Outreach DirectorExecutive Vice President

Robyn Diaz, JDChief Legal OfficerSenior Vice President

Pam Dotson, RN, MBAChief Nursing OfficerSenior Vice President & Chief Nursing Officer

Keith PerryChief Information OfficerSenior Vice President

Pat KeelChief Financial OfficerSenior Vice President

Shari CapersVice President, Strategic Planning & Decision Support

Victor Santana, MDVice President of Clinical TrialsAssociate Director of Clinical Research

James Boyett, PhDChair, Biostatistics

Andrew Davidoff, MDChair, Surgery

David Ellison, MD, PhDChair, Pathology

Amar Gajjar, MDCo-chair, Oncology

Doug Green, PhDChair, Immunology

Gerard Grosveld, PhDChair, Genetics

Kip Guy, PhD Chair, Chemical Biology & Therapeutics

Thomas Merchant, DO, PhD Chair, Radiation Oncology

James Morgan, PhDChair, Developmental Neurobiology

Sean Phipps, PhDChair, Psychology

Ching-Hon Pui, MDChair, Oncology

Mary Relling, PharmDChair, Pharmaceutical Sciences

Les Robison, PhDChair, Epidemiology & Cancer Control

Charles Sherr, MD, PhDChair, Tumor Cell Biology

J. Paul Taylor, MD, PhDChair, Cell & Molecular Biology

Elaine Tuomanen, MDChair, Infectious Diseases

Weiss, Mitchell, MD, PhDChair, Hematology

Stephen White, DPhil Chair, Structural BiologyDean of the Graduate School

Jinghui Zhang, PhDChair, Computational Biology

Suzanne Baker, PhDDirector, Brain Tumor Research Division

Michael Dyer, PhD Director, Developmental Biology Division

Terrence Geiger, MD, PhDMedical Director, Clinical Pathology

Melissa Hudson, MDDirector, Cancer Survivorship Division

Matthew Krasin, MDDirector, Radiation Dosimetry Core

Alberto Pappo, MDDirector, Solid Tumor Division

Charles Mullighan, MBBS, MDCo-Leader, Hematological Malignancies Program

Martine Roussel, PhDCo-Leader, Cancer Genetics

Brenda Schulman, PhDCo-Leader, Cancer Genetics

Jonathan McCullers, MDAdjunct Faculty, Infectious Diseases


ALSACExecutive Leadership Team

Richard C. Shadyac Jr.President and Chief Executive Officer

Emily CallahanChief Marketing Officer

Emily S. GreerChief Administrative Officer

Sara HallChief Legal Officer

Martin HandChief Donor Officer

Sue HarpoleChief Development Officer

Robert MachenChief Information Officer

Anurag PanditChief Investment Officer

Jeffrey T. PearsonChief Financial Officer

George P. ShadrouiChief Strategy Officer

Senior Vice Presidents

Christopher BoysenField Operations

Wilfred BusbyCall Centers

Mark EdmiastonFitness & Endurance Programs

Steele FordStrategic Partnerships

Steven FroehlichNational Direct Marketing

Melanee HannockInnovation and Strategy

Diane HeymanHuman Resources

Mike SiegelBrand and Creative

Vice Presidents

Brenda AbshureExecutive Office Operations

Aimee HallInteractive Group

Betty MacDougallCEO Affairs and Executive Communications

Kelly SchulzCommunications

Regina WatsonGift Planning

St. Jude Patient

Devonmedulloblastoma


ALSAC/St. Jude Children’s Research Hospital

Combined Financial Highlights for Fiscal Year 2015

Revenues 2Years Ended

015June 30 (in thousands)

2014 Total Support $1,064,761 $983,614

105,577 97,421

85,347 80,938

27,994 390,644

16,172

1,299,851

33,961

1,586,578

Net Patient Service Revenue

Research Grants

Net Investment Income

Other

Total Revenues

Expenses

Program Expenses

Patient Care Services

Research

Education, Training & Community Support

Total Program Expenses

Fundraising

Administrative & General

Total Expenses

Gain (loss) on Disposal of Property & Equipment

Change in Net Assets

Beginning Net Assets

Ending Net Assets

367,779

339,671

82,503

789,953

188,275

125,278

1,103,506

(918)

195,427

3,559,817

3,755,244

317,682

323,357

81,265

722,304

166,560

108,537

997,401

(1,689)

587,488

2,972,329

3,559,817

St. Jude Patient

Tashacute lymphoblastic leukemia


There are great children’s hospitals. There are great research institutions. There are great charities.

St. Jude Children’s Research Hospital is all three.

St. Jude won’t stop looking for cures for cancer and other life-threatening diseases. St. Jude will share its research with the world so that children everywhere can benefit from these discoveries. And families will never pay St. Jude for anything. We cover the cost of treatment, travel, housing and food so that all a family has to worry about is helping their child live.

Your generosity and support makes this possible. Thank you for being a part of our mission.

Visit stjude.org today to find out how you can make a difference.

To view the interactive Finding cures. Saving children.® 2015 St. Jude Annual Report, visit the App Store and download the St. Jude Publications App on your iPad.


2015 st. jude annual report

Documents